Skip to content
Triangle logo TriangleGet started
← Study library

NCT00002895 · CITED IN SOURCE DOCUMENTS

Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE3
Status at capture
COMPLETED
Registry last update
2013-12-04

RATIONALE: It is not yet known if treatment for recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer is more effective if it is begun when blood levels of CA 125 become elevated rather than waiting for other indicators of disease recurrence. PURPOSE: This randomized phase III trial is studying early chemotherapy based on blood levels of CA 125 alone to see how well it works compared to chemotherapy based on conventional clinical indicators in patients with recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part
eligibility Criteria
DISEASE CHARACTERISTICS: * Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal cancer * Achieved complete remission with normal CA 125 after first-line platinum-containing chemotherapy * Prior participation in the following clinical trials is allowed: * MRC-ICON2 (carboplatin vs cyclophosphamide, doxorubicin, and cisplatin for advanced disease) * MRC-ICON3 (paclitaxel with carboplatin in first-line therapy for advanced disease) * MRC-ICON5 (carboplatin and paclitaxel vs triplet and sequential doublet combinations of chemotherapy) * No prior participation in MRC-ICON1 (adjuvant chemotherapy for early-stage ovarian cancer) PATIENT CHARACTERISTICS: Age: * Not specified Performance status: * Not specified Hematopoietic: * Not specified Hepatic: * Not specified Renal: * Not specified Other: * No prior or concurrent malignancy within the past 5 years that is likely to preclude study treatment or comparisons except for nonmelanoma skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * See Disease Characteristics Endocrine therapy: * Not specified Radiotherapy: * Not specified Surgery: * Not specified
healthy Volunteers
false
sex
FEMALE
std Ages
  1. CHILD
  2. ADULT
  3. OLDER_ADULT
Treatment arms and interventions
interventions
  1. name
    chemotherapy
    type
    DRUG
Study design
allocation
RANDOMIZED
primary Purpose
TREATMENT
Enrollment
count
1400
type
ESTIMATED
Registered outcome plans (not posted results)
primary Outcomes
  1. measure
    Benefit of early chemotherapy
  2. measure
    Overall survival
  3. measure
    Quality of life
Full study description
brief Summary
RATIONALE: It is not yet known if treatment for recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer is more effective if it is begun when blood levels of CA 125 become elevated rather than waiting for other indicators of disease recurrence. PURPOSE: This randomized phase III trial is studying early chemotherapy based on blood levels of CA 125 alone to see how well it works compared to chemotherapy based on conventional clinical indicators in patients with recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer.
detailed Description
OBJECTIVES: * Compare the benefit of early chemotherapy based on CA 125 level only vs chemotherapy based on conventional clinical indicators in patients with relapsed ovarian epithelial, fallopian tube, or primary peritoneal cancer. * Compare the overall survival of patients treated with these regimens. * Compare the quality of life of patients treated with these regimens. OUTLINE: This is a randomized, multicenter study. Patients whose CA 125 levels rise to more than two times the upper limit of normal are randomized to one of two treatment arms. * Arm I: The clinician is informed of the initial rise in CA 125 level. A confirmatory test is performed immediately. Within 4 weeks of the initial CA 125 elevation, patients with a second confirmed elevation receive treatment for recurrent disease according to standard local practice. Patients with a normal CA 125 on the confirmatory test receive no treatment until clinically indicated. * Arm II: The clinician is blinded to the CA 125 results. Patients undergo normal monitoring. When clinically indicated, patients commence treatment according to standard local practice. Quality of life is assessed at baseline, at each follow-up visit, and, if treatment is instituted, before each chemotherapy course. Patients are followed every 3 months. PROJECTED ACCRUAL: A total of 1,400 patients will be accrued for this study.
Source references
references
  1. citation
    Markman M, Petersen J, Belland A, Burg K. CA-125 monitoring in ovarian cancer: patient survey responses to the results of the MRC/EORTC CA-125 Surveillance Trial. Oncology. 2010;78(1):1-2. doi: 10.1159/000292352. Epub 2010 Mar 6. No abstract available.
    pmid
    20215782
    type
    BACKGROUND
  2. citation
    Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MK, Swart AM; MRC OV05; EORTC 55955 investigators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010 Oct 2;376(9747):1155-63. doi: 10.1016/S0140-6736(10)61268-8.
    pmid
    20888993
    type
    RESULT
  3. citation
    Rustin GJ, van der Burg ME: A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). [Abstract] J Clin Oncol 27 (Suppl 18): A-1, 2009.
    type
    RESULT
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-0fecf98d393d19f69cec
      requested nct id
      NCT00002895
      primary nct id
      NCT00002895
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      d626fa717739cf3dda8aebd26e3ffaf109ec1e006da0173aee8007b288898b2c
      payload sha256
      cfef1fa2179588d54b8f7285625e66add61c1b0ec123b23d686a6f3f0d5f5acc
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-0fecf98d393d19f69cec
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT00002895
      occurrences
      1. context exact
        s. delayed initiation of treatment):</p><div class="pdq-content-list"><ol id="_953"><li>A trial by the Medical Research Council (MRC) (<a href="/clinicaltrials/NCT00002895">MRC-OV05</a>) and the European Organisation for Research and Treatment of Cancer examined the consequences of early treatment for an elevated CA-125 level
        end
        246772
        exact text
        NCT00002895
        start
        246761
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/ff9ceeeae0fbdc33fd.html
      source file sha256
      d626fa717739cf3dda8aebd26e3ffaf109ec1e006da0173aee8007b288898b2c
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:22:10.059252+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      2a71979c192f62071168507c9e3b23e31a4e8fe2e21ca0f7ee294555ff0250c9
      source title
      Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: May 14, 2025
        datetime
        2025-05-14T12:00:00Z
        display
        May 14, 2025

    Preserved source evidence · Not medical advice